JANSSEN ANNOUNCES U.S. FDA APPROVAL OF TREMFYA™ (GUSELKUMAB) FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS

• TREMFYA™ is the first and only biologic approved that selectively blocks interleukin (IL)-23.
• Seven out of ten patients receiving TREMFYA™ achieved at least 90 percent improvement in skin clearance at week 16.
• Nearly three quarters of TREMFYA™-treated patients demonstrated at least 90 percent clearer skin at week 48.
• TREMFYA™ demonstrated superior results in skin clearance compared with Humira^®* (adalimumab) in head-to-head analyses at weeks 16, 24 and 48.

 

Click HERE to read more.